Study reveals novel mechanism that activates KEAP1 to drive NRF2 degradation, overcoming a longstanding barrier in targeting NRF2-driven tumors Preclinical data show antitumor activity and enhanced ...

Researchers from Japan Tobacco Inc. presented the discovery and preclinical characterization of novel highly potent Keap1-Nrf2 protein-protein interaction (PPI) inhibitors.

Sepsis is a complex clinical syndrome characterized by dysregulated immune responses, systemic inflammation, and multi-organ dysfunction. It involves intricate interactions among multiple signaling ...